EpimAb Biotherapeutics is Granted US Patent on Core Bispecific Antibody Technology

April 24, 2019 Off By BusinessWire

Patent protects EpimAb’s core technology FIT-Ig^®
and its entire bispecific pipeline with a broad composition of matter
claim

SHANGHAI–(BUSINESS WIRE)–EpimAb Biotherapeutics, an emerging biopharmaceutical company based in
Shanghai, announced today that the United States Patent and Trademark
Office (USPTO) has granted the U.S. Patent No. 10,266,608 entitled
“Fabs-In-Tandem Immunoglobulin and Uses Thereof”. Based on EpimAb’s
globally filed first application, this patent broadly covers bispecific
antibodies obtained utilizing the company’s FIT-Ig^®
technology in a composition of matter claim.

“This patent underscores the novelty of EpimAb’s approach in bispecific
antibody generation and forms an important foundation of EpimAb’s
growing IP portfolio,” said Dr. Chengbin Wu, Founder and CEO of EpimAb
Biotherapeutics. “The first granted patent in a major pharmaceutical
market like the US therefore represents a significant milestone for
EpimAb and takes us another step towards our goal to become a leading
innovator in cancer biologics.”

EpimAb is developing multiple programs based on its FIT-Ig^®
platform for the treatment of various cancers. Its most advanced product
candidate EMB-01, a cMet/EGFR bispecific with a novel mechanism of
action was discovered and rapidly developed to the clinic by EpimAb. It
is currently being investigated in a clinical Phase I/II trial in the
USA and China. A second FIT-Ig molecule is currently under preclinical
development with further molecules following soon, rapidly growing
EpimAb’s pipeline of bispecific antibodies.

About EpimAb Biotherapeutics, Inc.

EpimAb Biotherapeutics is a privately-owned biopharmaceutical R&D
company based in Shanghai and Suzhou with a proprietary unique and
efficient technology called FIT-Ig^® (Fabs-In-Tandem
Immunoglobulin) to generate bispecific molecules with antibody-like
properties, without any mutations, peptide linkers, or non-Ig sequences.
With this platform EpimAb is creating a pipeline of its own novel
bispecific antibody therapeutics focused around immuno-oncology and
other areas of high value to patients. EpimAb is also committed to
diversifying its pipeline through selective licensing of its platform to
partners worldwide. For further information, please visit www.epimab.com